Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 10
Submit an article Journal homepage
398
Views
6
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia

Fie J. VojdemanDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark; ;Department of Clinical Biochemistry, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark; Correspondence[email protected]
,
Sarah E. M. HermanHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA;
,
Nikolai KirkbyDepartment of Microbiology, Rigshospitalet, Copenhagen, Denmark;
,
Adrian WiestnerHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA;
,
Mars B. van t’ VeerDepartment of Hematology, Leiden University Medical Centre, Leiden, The Netherlands;
,
Geir E. TjønnfjordDepartment of Hematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway;
,
Maija A. Itälä-RemesDepartment of Hematology, Turku Central University Hospital, Turku, Finland;
,
Eva KimbyDivision of Hematology, Department of Medicine at Huddinge, Karolinska Institute, Stockholm, Sweden;
,
Mohammed Z. FarooquiHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA;
,
Aaron PolliackDepartment of Hematology, Hadassah University Hospital, Hebrew University Medical School, Jerusalem, Israel;
,
Ka Lung WuDepartment of Hematology, Stuivenberg Hospital, Antwerpen, Belgium;
,
Jeanette K. DoorduijnDepartment of Hematology, Erasmus MC Cancer Center, Rotterdam, The Netherlands;
,
Wendimagegn G. AlemayehuHOVON Data Centre, Erasmus MC, Rotterdam, The Netherlands;
,
Shulamiet WittebolDepartment of Internal Medicine, Gelderse Vallei Hospital, Amersfoort, The Netherlands;
,
Tomas KozakDepartment of Clinical Hematology, Third Faculty of Medicine, Charles University Hospital Kralovske Vinohrady, Prague, Czech Republic;
,
Jan WalewskiLymphoid Malignancies, Maria Sklodowska – Curie Memorial Institute and Oncology Centre, Warszawa, Poland;
,
Martine C. J. Abrahamse-TestrooteHOVON Data Centre, Erasmus MC, Rotterdam, The Netherlands;
,
Marinus H. J. van OersDepartment of Hematology, Academisch Medisch Centrum, Amsterdam, The Netherlands
,
Christian H. GeislerDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark;
&
Carsten U. NiemannDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark;
show all
Pages 2356-2362 | Received 22 Nov 2016, Accepted 15 Jan 2017, Published online: 07 Feb 2017

References

  • Xia MQ, Hale G, Lifely MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J. 1993;293:633–640.
  • Treumann A, Lifely MR, Schneider P, et al. Primary structure of CD52. J Biol Chem. 1995;270:6088–6099.
  • Klabusay M, Sukova V, Coupek P, et al. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. Cytometry B. 2007;72B:363–370.
  • Bandala-Sanchez E, Zhang Y, Reinwald S, et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol. 2013;14:741–748.
  • Albitar M, Do KA, Johnson MM, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004;101:999–1008.
  • Alatrash G, Albitar M, O’Brien S, et al. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010;148:386–393.
  • Bloehdorn J, Sill M, Langer C, et al. High CD52 mRNA expression is an adverse prognostic factor in fludarabine-refractory CLL treated with alemtuzumab on the Gcllsg CLL2H trial. Blood 2013;122:21. Abstract 1618.
  • Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16:169–176.
  • Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
  • Geisler CH, van T, Veer MB, Jurlander J, et al. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. Blood. 2014;123:3255–3262.
  • West B, Welch K, Galecki A. Linear mixed models: a practical guide using statistical software. Boca raton (FL): Chapman and Hall/CRC Press;2008.
  • Herman SEM, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28:2188–2196.
  • Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563–574.
  • Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease . Br J Haematol. 2003;123:850–857.
  • Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49–62.
  • Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
  • Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2016;125:2497–2507.
  • Guo A, Lu P, Galanina N, et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget. 2016;7:4598–4610.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
  • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
  • Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica. 2015;100:1495–1507.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.